SCHEMBL10192186

SCHEMBL10192186

Cc1ccc(NC(=O)c2cc(C)on2)cc1

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
NPC1 O15118 7/20 1.00
RAB9A P51151 7/20 1.00
ALDH1A1 P00352 6/20 1.00
TP53 P04637 2/20 1.00
GLA P06280 1/20 1.00
HTT P42858 1/20 1.00
SMN1; SMN2 Q16637 5/20 0.73
NFKB1 P19838 1/20 0.73
NFKB2 Q00653 1/20 0.73
RELA Q04206 1/20 0.73
L3MBTL1 Q9Y468 1/20 0.65
MAPT P10636 4/20 0.65
USP2 O75604 1/20 0.64
HSD17B10 Q99714 3/20 0.62
KDM4E B2RXH2 2/20 0.62
HPGD P15428 2/20 0.62
LMNA P02545 2/20 0.61
POLB P06746 1/20 0.60
GAA P10253 1/20 0.60

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL8267173 0.95 NPC1 (0.90) NPC1RAB9AALDH1A1TP53GLA
SCHEMBL8267152 0.89 NPC1 (0.79) NPC1RAB9AALDH1A1TP53GLA
SCHEMBL13321363 0.89 RAB9A (0.79) NPC1RAB9AALDH1A1TP53GLA
SCHEMBL8266861 0.87 NPC1 (0.77) NPC1RAB9AALDH1A1TP53GLA
SCHEMBL8266868 0.87 RAB9A (0.77) NPC1RAB9AALDH1A1TP53GLA
SCHEMBL1394901 0.86 NPC1 (0.75) NPC1RAB9AALDH1A1TP53GLA
SCHEMBL8267289 0.84 RAB9A (1.00) NPC1RAB9AALDH1A1TP53GLA
SCHEMBL17117170 0.84 NPC1 (0.73) NPC1RAB9AALDH1A1TP53GLA
SCHEMBL8267163 0.83 SMN1; SMN2 (0.88) NPC1RAB9AALDH1A1TP53GLA
SCHEMBL5188882 0.83 NPC1 (0.71) NPC1RAB9AALDH1A1TP53GLA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20120009142-A1 METHODS FOR TREATING HEPATITIS C PTC THERAPEUTICS, INC. (US) 2012-01-12 US disclosed
US-7973069-B2 Methods for treating hepatitis C PTC THERAPEUTICS, INC. (US) 2011-07-05 US disclosed
US-20100305100-A1 METHODS FOR TREATING HEPATITIS C PTC THERAPEUTICS, INC. (US) 2010-12-02 US disclosed
US-20100292187-A1 METHODS FOR TREATING HEPATITIS C PTC THERAPEUTICS, INC. (US) 2010-11-18 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120009142-A1 METHODS FOR TREATING HEPATITIS C OAT, HAVCR2, HCCS NPC1 297/4885RAB9A 3975/4885ALDH1A1 591/4885
US-20100292187-A1 METHODS FOR TREATING HEPATITIS C HAVCR2, EIF2AK2, MAVS NPC1 87/4885RAB9A 2829/4885ALDH1A1 1497/4885
US-20100305100-A1 METHODS FOR TREATING HEPATITIS C HAVCR2, EIF2AK2, MAVS NPC1 87/4885RAB9A 2829/4885ALDH1A1 1497/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.